Cell>Point News & Publications
Diagnostic Imaging
Posted on: September 19th, 2018
CENTENNIAL, Colorado, September 18, 2018 – CellPoint announced today that it has entered into an automated production agreement with KP Pharmaceutical Technology, Inc. to produce 1mg vials of its lead agent Oncardia®(ethylenedicysteine-glucosamine). CellPoint is currently completing Phase 2b and 3 nuclear imaging trials with 99mTc-Oncardia® in both cardiology and oncology imaging. The new formulation will simplify the…
Read More
Posted on: March 19th, 2018
Published March 19, 2018, Hindawi Contrast Media & Molecular Imaging https://cellpointweb.com/wp-content/uploads/2019/11/Noninferiority-of-99mTc-Ethylenedicystein.pdf
Read More
Posted on: October 3rd, 2016
Oncotarget, Advance Publications 2016 https://cellpointweb.com/wp-content/uploads/2019/11/12413-186535-1-PB-2016-EC-G-Paper.pdf
Read More
Posted on: August 25th, 2016
CENTENNIAL, Colo., August 24, 2016 – Cell>Point today announced it has entered into license agreements with Vyripharm Biopharmaceuticals for the use of its In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology to develop applications in combination with cannabinoids for nuclear imaging and therapeutic applications for neurologic disorders including, but not limited to, posttraumatic stress disorder (“PTSD”),…
Read More
Posted on: June 17th, 2016
CENTENNIAL, Colo., June 16, 2016 – Cell>Point today announced that it has entered into an exclusive license agreement for China, Hong Kong and Macau with United Eastern Pharmaceutical (UEP), a company representing a consortium from the U.S. and China. The license agreement covers Cell>Point’s diagnostic radiopharmaceutical Oncardia® (ethylenedicysteine-glucosamine) which was developed for labeling with technetium-99m for…
Read More
Posted on: February 26th, 2015
CENTENNIAL, Colo., January 15, 2015 – Cell>Point announced today positive results following conclusion of a Head and Neck Cancer imaging trial for 99mTc-Oncardia® conducted pursuant to a physician initiated IND study at the University of Chicago Medical Center. The study imaged patients with squamous cell carcinoma of the head and neck (SCCHN) with technetium-99m- labeled Oncardia®…
Read More
Posted on: September 21st, 2014
Published: September 2014, Bio Medical Research International https://cellpointweb.com/wp-content/uploads/2019/11/Patched-Targeting-Peptides-for-Imaging-and-Treatment-of-Hedgehog-Postive-Breast-Tumors.pdf
Read More
Posted on: April 12th, 2013
CENTENNIAL, Colo., April 9, 2013—Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri. The study imaged patients with technetium-99m-labeled Ethylenedicysteine-Glucosamine (99mTc-EC-G), Cell>Point’s proprietary nuclear imaging product candidate, which is target specific for detecting the presence and extent of schemia in patients with Coronary…
Read More
Posted on: March 13th, 2013
Third License Completes the Company’s Initiative to Secure a Strong Pharmaceutical Partner for the South Korean Market CENTENNIAL, Colo., March 11, 2013—Cell>Point announced today that it entered into a license agreement on December 17,2012 with Hanmi Pharmaceutical Co., Ltd (Hanmi) who is headquartered in Seoul, Korea. The license agreement also includes HYUN IMC as a party (who Cell>Point previously…
Read More
Posted on: January 30th, 2013
Published: January 2013, Vol. 20, No. 1, Academic Radiology https://cellpointweb.com/wp-content/uploads/2019/11/Deveopment-of-99mTc-EC-tyrosine-for-Early-Detection-of-Breast-Cancer-Tumror-Response-to-the-Anticancer-Drug-Melphalan.pdf
Read More
